Phase 1 Study of TROP2-CAR-NK Cells for Advanced Solid Tumors
This study, called TROPIKANA, is a Phase 1 trial testing a new cell therapy called TROP2-CAR-NK Cells for people with advanced solid tumors that have progressed after standard treatments. Researchers want to find the safest and most effective dose of TROP2-CAR-NK Cells. You would receive TROP2-CAR-NK Cells along with other medications like Rimiducid, Fludarabine phosphate, and Cyclophosphamide, all given through a vein (IV). The main goal is to check for any side effects and find the best dose. Researchers will also look at how well the treatment works against the cancer and how long the cells stay in your body. This study is open to adults aged 18 and older with certain types of solid tumors. The study is currently unclear if it is recruiting.
- Study design
- This is a Phase 1 study designed to find the best dose of TROP2-CAR-NK cells. It plans to enroll 54 participants.
- What's involved
- Participants will be monitored for adverse events through study completion, which is an average of 1 year.
- Compensation
- Not stated in the trial record.
- Follow-up
- Participants will be followed for adverse events through study completion, which is an average of 1 year.
AI-generated from the public study record. Only the study team can confirm whether you're eligible — confirm details with them before making decisions.
Phase 1 Dose Escalation and Expansion Study of TROP2 CAR Engineered IL15-transduced Cord Blood-derived NK Cells in Patients With Advanced Solid Tumors (TROPIKANA)
At a glance
Conditions
Where it's being run
1 sites across 1 statesStudy leadership
- Ecaterina Dumbrava, M D · PRINCIPAL_INVESTIGATOR · M.D. Anderson Cancer Center
Who to contact
Opens a ready-to-send draft in your own email app — review before sending.
What this trial measures
- Incidence of Adverse Events, Graded According to National Cancer Institute Common Terminology Criteria for Adverse Events (NCI CTCAE) Version (v) 5.0through study completion; an average of 1 year